Biogen to spin off hemophilia business

Biogen Inc. (NASDAQ:BIIB) said it plans to spin off its hemophilia business into a separate public company by early 2017. It intends to distribute shares in the still-unnamed company to Biogen stockholders.

The

Read the full 336 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE